Oxford Asset Management’s Seres Therapeutics MCRB Stock Holding History

Oxford Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$130K	Sell	1,818 -11,055	-86%	-$741K	0.02%	133
2019 Q4	$888K	Buy	12,873 +3,077	+31%	+$228K	0.02%	931
2019 Q3	$786K	Buy	+9,796	New	+$647K	0.02%	1066
2019 Q2	–	Sell	-522	Closed	-$72K	–	1863
2019 Q1	$72K	Buy	+522	New	+$63.6K	﹤0.01%	1586
2018 Q3	–	Sell	-2,597	Closed	-$455K	–	1839
2018 Q2	$455K	Sell	2,597 -492	-16%	-$80.4K	0.01%	1374
2018 Q1	$453K	Buy	3,089 +1,205	+64%	+$231K	0.01%	1281
2017 Q4	$387K	Buy	+1,884	New	+$387K	0.01%	1267
2017 Q2	–	Sell	-1,151	Closed	-$259K	–	1603
2017 Q1	$259K	Sell	1,151 -945	-45%	-$192K	0.01%	1243
2016 Q4	$415K	Buy	+2,096	New	+$457K	0.01%	616
2016 Q3	–	Sell	-1,749	Closed	-$1.02M	–	814
2016 Q2	$1.02M	Buy	+1,749	New	+$1.03M	0.03%	483
2015 Q4	–	Sell	-6,090	Closed	-$3.61M	–	915
2015 Q3	$3.61M	Hold	6,090	–	–	0.11%	187
2015 Q2	$5.05M	Buy	+6,090	New	+$5.31M	0.14%	172

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Oxford Asset Management's MCRB Position: Q1 2020 in Review

Oxford Asset Management reduced its Seres Therapeutics (MCRB) stake by 86% in Q1 2020, selling an estimated $741K and leaving 1,818 shares worth $130K. The position accounts for 0.02% of the portfolio, ranked #133.

Oxford Asset Management first reported a position in MCRB in Q2 2015 and has held it in 12 quarters since. The position peaked at $5.05M in Q2 2015. 77 funds tracked by Wall St. Rank hold MCRB as of Q1 2020.

Oxford Asset Management held 1,818 shares of Seres Therapeutics worth $130K as of Q1 2020.
Oxford Asset Management sold 11,055 Seres Therapeutics shares in Q1 2020, an estimated $741K.
Seres Therapeutics made up 0.02% of Oxford Asset Management's portfolio in Q1 2020, its #133 holding.
Oxford Asset Management first reported a position in Seres Therapeutics in Q2 2015 and has held it in 12 quarters since.
Oxford Asset Management's Seres Therapeutics position peaked at $5.05M in Q2 2015.
77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.